Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

Four perspectives from life sciences companies on multichannel engagement

August 23, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …
News
andrew_dillon

NICE Chief Sir Andrew Dillon to step down in 2020

August 22, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK pharma, UK< pharma

It’s the end of an era at the National Institute of Health and Care Excellence (NICE), the UK watchdog responsible …
News
gilead-sciences

Gilead challenges Government over patents on preventative HIV drug Truvada

August 22, 2019 Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents

Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …
News
1920px-hiv-budding-color

GSK’s two drug HIV regimen effective when administered every two months

August 22, 2019 Research and Development AIDS, GSK, HIV, ViiV Healthcare, viral supression

GSK’s long-acting, two-drug HIV regimen was as effective in supressing patient’s viral loads when administered every two months (eight weeks), …
News

NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation

August 21, 2019 Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …
News
teva_copy

Teva launch generic version of EpiPen for children

August 21, 2019 Research and Development Mylan, Teva, allergies, children, epipen, pharma

A generic version of Mylan’s EpiPen, manufactured by Teva, is now available for children weighing between 15kg and 30kg in …
News
astrazeneca_building_white

AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer

August 21, 2019 Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …
News
blood-1813410_960_720

NHS England to fund Hemlibra for patients with severe haemophilia

August 21, 2019 Research and Development Chugai, Hemlibra, Roche, haemophilia, pharma

NHS England is to fund Roche and Chugai Pharma UK’s haemophilia drug Hemlibra, for people with sever congenital haemophilia A …
News

Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

August 21, 2019 Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …
News
733px-reduction_gear

Finding the needle in the haystack of rare disease

August 19, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Genomenon, Rare Genomics Institute, pharma, rare disease

Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory …
Feature
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …
News
regeneron

Regeneron therapy halves LDL cholesterol levels in rare genetic condition

August 15, 2019 Research and Development Regeneron, evinacumab, pharma, rare disease

Regeneron has reported a strong showing for its investigational angiopoietin-like 3 (ANGPTL3) antibody evinacumab in the treatment of the rare …
News
lilly_building_with_american_flag_web

Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

August 15, 2019 Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …
News

FDA approve new drug for treatment-resistant TB

August 15, 2019 Research and Development FDA, TB, US, pharma, pretomanid, tuberculosis

The US FDA has approved BPaL, the TB Alliance’s treatment for drug-resistant tuberculosis (TB). The US regulator gave the go-ahead …
News
lynparza

Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations

August 14, 2019 Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025